Regentis Biomaterials closed a US $15MM Series D investment round. Funds will primarily support a pivotal U.S. clinical trial of GelrinC®, a cell-free implant for the treatment of articular knee cartilage injuries.
Studies concluded that, for patients with 2-level degenerative disc disease, cervical total disc replacement appears to be highly cost-effective vs. ACDF, and supports greater quality of life at less cost.Â
FDA tentatively scheduled a 2Q16 meeting of the Orthopaedic and Rehabilitation Devices Panel to review Cartiva’s Premarket Approval Application for the Synthetic Cartilage Implant in the treatment of great toe osteoarthritis.
OrthAlign entered into a multi-country distribution agreement with Smith & Nephew for its KneeAlign® Total Knee Arthroplasty component alignment technology.